Since the pioneering discovery of secretin-like activity by Bayliss and Starling in 1902, scientists have pursued the mysteries of gut-hormone biology, such that the peptide hormone–secreting ...

Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The "Glucagon-like Peptide 1 Market Report 2026" has been added to ResearchAndMarkets.com's offering. The glucagon-like peptide 1 (GLP-1) market has witnessed ...

Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss. Objective: Obesity affects more than 40 ...

In a recent article published in Science, researchers reviewed clinical studies on the advantages of glucagon-like peptide-1 (GLP-1) medicines beyond glycemic and weight control. GLP-1 medications, ...

Analysts remain intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they note it is too early to compare ...

Opko Health and Entera Bio have formalized their partnership as the biotechs prepare to take the first orally administered dual agonist glucagonlike-peptide 1 (GLP-1)/glucagon peptide into the clinic.

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...

Peptide drugs are used to treat a variety of health conditions. Some may even help people who are overweight and obese lose weight and manage obesity-related conditions. A peptide is a small chain of ...

Menopausal hormone therapy after a diagnosis of breast cancer in women with a BRCA pathogenic variant and risk of death. Adjusted hazard ratios of incidence of composite obesity-related cancer and all ...